Tumor Mutational Burden in Non-small Cell Lung Cancer-the Pathologist's Point of View

Overview

Journal Transl Lung Cancer Res

Date 2018 Dec 4

PMID 30505716

Citations 7

Authors

Frederique Penault-Llorca

Nina Radosevic-Robin

Affiliations

Soon will be listed here.

Abstract

In non-small cell lung cancer (NSCLC), the pathologist has contributed to the development of personalized medicine from the determination of the right histological type to and molecular screening for targeted therapies. With the development of immunotherapies, pathologists intervene forefront with programmed death-ligand 1 (PD-L1) immunohistochemical testing, companion test for pembrolizumab monotherapy, first line and complementary test to the other programmed cell death-1 (PD-1) PD-L1 inhibitors. Recently, tumor mutational burden has emerged as a promising tool to evaluate sensitivity to immunotherapy (IO). The pathologist has a crucial role in the setting of tumor mutational burden (TMB) testing for the selection and the preparation of the sample for high throughput molecular analysis, and in the first steps of the next-generation sequencing (NGS) workflow.

Citing Articles

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer.

Liang H, Xu Y, Chen M, Zhao J, Zhong W, Liu X Front Immunol. 2022; 12:749461.

PMID: 35356154 PMC: 8959482. DOI: 10.3389/fimmu.2021.749461.

Molecular Pathology of Lung Cancer.

Saller J, Boyle T Cold Spring Harb Perspect Med. 2021; 12(3).

PMID: 34751163 PMC: 8886739. DOI: 10.1101/cshperspect.a037812.

Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles.

Ling B, Ye G, Zhao Q, Jiang Y, Liang L, Tang Q Front Mol Biosci. 2021; 7:603701.

PMID: 33505988 PMC: 7832236. DOI: 10.3389/fmolb.2020.603701.

Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations.

Wang Y, Li J, Zhou Y, Cao S, Ling X, Zhang Y Ann Transl Med. 2020; 8(20):1297.

PMID: 33209877 PMC: 7661900. DOI: 10.21037/atm-20-6172.

Tumor mutational burden in lung cancer: a systematic literature review.

Willis C, Fiander M, Tran D, Korytowsky B, Thomas J, Calderon F Oncotarget. 2019; 10(61):6604-6622.

PMID: 31762941 PMC: 6859921. DOI: 10.18632/oncotarget.27287.

References

Lievre A, Artru P, Guiu M, Laurent-Puig P, Merlin J, Sabourin J . The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. Eur J Cancer. 2013; 49(9):2126-33. DOI: 10.1016/j.ejca.2013.02.016. View

Cree I, Deans Z, Ligtenberg M, Normanno N, Edsjo A, Rouleau E . Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014; 67(11):923-31. PMC: 4215286. DOI: 10.1136/jclinpath-2014-202404. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Travis W, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y . Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2012; 137(5):668-84. PMC: 4509741. DOI: 10.5858/arpa.2012-0263-RA. View

Hersom M, Jorgensen J . Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Ther Drug Monit. 2017; 40(1):9-16. DOI: 10.1097/FTD.0000000000000460. View

Hellmann M, Ciuleanu T, Pluzanski A, Lee J, Otterson G, Audigier-Valette C . Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378(22):2093-2104. PMC: 7193684. DOI: 10.1056/NEJMoa1801946. View

Chen H, Luthra R, Goswami R, Singh R, Roy-Chowdhuri S . Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers (Basel). 2015; 7(3):1699-715. PMC: 4586792. DOI: 10.3390/cancers7030859. View

Lindeman N, Cagle P, Aisner D, Arcila M, Beasley M, Bernicker E . Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer,.... J Thorac Oncol. 2018; 13(3):323-358. DOI: 10.1016/j.jtho.2017.12.001. View

Takamochi K, Takahashi F, Suehara Y, Sato E, Kohsaka S, Hayashi T . DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. Lung Cancer. 2017; 110:26-31. DOI: 10.1016/j.lungcan.2017.05.016. View

10.

Dietel M, Bubendorf L, Dingemans A, Dooms C, Elmberger G, Garcia R . Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2015; 71(2):177-84. PMC: 4752623. DOI: 10.1136/thoraxjnl-2014-206677. View

11.

Long E, Ilie M, Hofman V, Lassalle S, Butori C, Alsubaie S . [Role of the surgical pathologist for tissue management in oncology]. Bull Cancer. 2013; 100(9):837-45. DOI: 10.1684/bdc.2013.1803. View

12.

Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E . Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017; 12(11):e0188174. PMC: 5697854. DOI: 10.1371/journal.pone.0188174. View

13.

Einaga N, Yoshida A, Noda H, Suemitsu M, Nakayama Y, Sakurada A . Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation. PLoS One. 2017; 12(5):e0176280. PMC: 5428915. DOI: 10.1371/journal.pone.0176280. View

14.

Zhang P, Lehmann B, Shyr Y, Guo Y . The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies. Int J Genomics. 2017; 2017:1926304. PMC: 5299160. DOI: 10.1155/2017/1926304. View

15.

Voong K, Feliciano J, Becker D, Levy B . Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. Ann Transl Med. 2017; 5(18):376. PMC: 5635257. DOI: 10.21037/atm.2017.06.48. View

16.

Lhermitte B, Egele C, Weingertner N, Ambrosetti D, Dadone B, Kubiniek V . Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment. Virchows Arch. 2016; 470(1):21-27. DOI: 10.1007/s00428-016-2042-6. View

17.

Jennings L, Arcila M, Corless C, Kamel-Reid S, Lubin I, Pfeifer J . Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017; 19(3):341-365. PMC: 6941185. DOI: 10.1016/j.jmoldx.2017.01.011. View

18.

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

19.

van Krieken J, Rouleau E, Ligtenberg M, Normanno N, Patterson S, Jung A . RAS testing in metastatic colorectal cancer: advances in Europe. Virchows Arch. 2015; 468(4):383-96. PMC: 4830882. DOI: 10.1007/s00428-015-1876-7. View

20.

Bonneville R, Krook M, Kautto E, Miya J, Wing M, Chen H . Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2018; 2017. PMC: 5972025. DOI: 10.1200/PO.17.00073. View